Century Therapeutics’ (IPSC) Market Perform Rating Reiterated at Leerink Partners

Leerink Partners reissued their market perform rating on shares of Century Therapeutics (NASDAQ:IPSC) in a research report released on Monday morning,Benzinga reports. Leerink Partners currently has a $2.00 price target on the stock, down from their previous price target of $7.00.

Several other equities research analysts have also weighed in on the company. Wall Street Zen lowered Century Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 20th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Century Therapeutics in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $3.40.

Century Therapeutics Price Performance

NASDAQ IPSC opened at $0.52 on Monday. Century Therapeutics has a 12 month low of $0.34 and a 12 month high of $1.83. The company has a market capitalization of $45.13 million, a P/E ratio of -1.62 and a beta of 1.80. The company’s 50 day simple moving average is $0.54 and its 200 day simple moving average is $0.55.

Century Therapeutics (NASDAQ:IPSC) last issued its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. Century Therapeutics had a negative net margin of 19.10% and a negative return on equity of 10.01%. On average, analysts anticipate that Century Therapeutics will post -1.61 earnings per share for the current year.

Institutional Trading of Century Therapeutics

A number of hedge funds have recently modified their holdings of IPSC. Bank of America Corp DE grew its holdings in shares of Century Therapeutics by 109.1% during the fourth quarter. Bank of America Corp DE now owns 66,043 shares of the company’s stock valued at $67,000 after buying an additional 34,466 shares in the last quarter. Nuveen LLC acquired a new stake in Century Therapeutics during the 1st quarter worth about $75,000. AQR Capital Management LLC boosted its position in Century Therapeutics by 358.9% during the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock worth $53,000 after acquiring an additional 86,875 shares during the period. Goldman Sachs Group Inc. grew its stake in Century Therapeutics by 26.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock valued at $86,000 after acquiring an additional 38,052 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in shares of Century Therapeutics by 101.2% in the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after purchasing an additional 142,953 shares during the period. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.